JP2024525611A5 - - Google Patents
Info
- Publication number
- JP2024525611A5 JP2024525611A5 JP2024500479A JP2024500479A JP2024525611A5 JP 2024525611 A5 JP2024525611 A5 JP 2024525611A5 JP 2024500479 A JP2024500479 A JP 2024500479A JP 2024500479 A JP2024500479 A JP 2024500479A JP 2024525611 A5 JP2024525611 A5 JP 2024525611A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- oligonucleotide
- optionally
- complex according
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163219999P | 2021-07-09 | 2021-07-09 | |
| US63/219,999 | 2021-07-09 | ||
| PCT/US2022/073527 WO2023283613A1 (en) | 2021-07-09 | 2022-07-08 | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024525611A JP2024525611A (ja) | 2024-07-12 |
| JP2024525611A5 true JP2024525611A5 (https=) | 2025-07-16 |
Family
ID=84802088
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024500479A Pending JP2024525611A (ja) | 2021-07-09 | 2022-07-08 | 筋標的化複合体およびジストロフィノパチーを処置するためのその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240318176A1 (https=) |
| EP (1) | EP4367147A4 (https=) |
| JP (1) | JP2024525611A (https=) |
| KR (1) | KR20240032945A (https=) |
| CN (1) | CN118355035A (https=) |
| AU (1) | AU2022307086A1 (https=) |
| CA (1) | CA3226365A1 (https=) |
| IL (1) | IL309937A (https=) |
| MX (1) | MX2024000494A (https=) |
| WO (1) | WO2023283613A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3108282A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| SG11202100928QA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| JP2024525608A (ja) | 2021-07-09 | 2024-07-12 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体および製剤 |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| AU2024299328A1 (en) | 2023-07-21 | 2026-01-22 | Marrow Therapeutics, Inc. | Hematopoietic cell targeting conjugates and related methods |
| WO2025160275A1 (en) | 2024-01-24 | 2025-07-31 | Arrowhead Pharmaceuticals, Inc. | Anti-transferrin receptor antibodies, conjugates thereof, and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005058244A2 (en) * | 2003-12-15 | 2005-06-30 | Alexion Pharmaceuticals, Inc. | Novel anti-dc-sign antibodies |
| WO2008073300A2 (en) * | 2006-12-08 | 2008-06-19 | Lexicon Pharmaceuticals, Inc. | Monoclonal antibodies against angptl3 |
| BR112013014527A2 (pt) * | 2010-12-20 | 2017-03-07 | Genentech Inc | anticorpo isolado, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica, uso do imunoconjugado, método para tratamento de um indivíduo que tem um câncer positivo para mesotelina, para inibição de proliferação de uma célula positiva para mesotelina, para detecção de mesotelina humana em uma amostra biológica e para detectar um câncer positivo para mesotelina |
| RU2014109038A (ru) * | 2011-08-23 | 2015-09-27 | Рош Гликарт Аг | Антитела к хондроитинсульфат протеогликану меланомы |
| CA2861247C (en) * | 2011-12-28 | 2021-11-16 | Nippon Shinyaku Co., Ltd. | Antisense nucleic acids |
| AR099625A1 (es) * | 2014-03-21 | 2016-08-03 | Lilly Co Eli | Anticuerpos de il-21 |
| JP7015244B2 (ja) * | 2016-03-22 | 2022-02-02 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | プロテアーゼ活性化ｔ細胞二重特異性分子 |
| MX2020003130A (es) * | 2017-09-22 | 2020-09-25 | Avidity Biosciences Inc | Composiciones y metodos de induccion de salto de exon en acidos nucleicos-polipeptidos. |
| CA3108282A1 (en) * | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| IL280536B2 (en) * | 2018-08-02 | 2024-12-01 | Dyne Therapeutics Inc | Complexes targeting transferrin receptor and uses thereof |
| WO2020219820A1 (en) * | 2019-04-25 | 2020-10-29 | Avidity Biosciences, Inc. | Nucleic acid compositions and methods of multi-exon skipping |
| CA3163608A1 (en) * | 2020-01-10 | 2021-07-15 | Romesh R. Subramanian | Muscle-targeting complexes and uses thereof |
| JP7780691B2 (ja) * | 2020-01-10 | 2025-12-05 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
| MX2023000984A (es) * | 2020-07-23 | 2023-05-03 | Dyne Therapeutics Inc | Complejos dirigidos al musculo y usos de los mismos para el tratamiento de distrofinopatias. |
-
2022
- 2022-07-08 JP JP2024500479A patent/JP2024525611A/ja active Pending
- 2022-07-08 KR KR1020247004290A patent/KR20240032945A/ko active Pending
- 2022-07-08 MX MX2024000494A patent/MX2024000494A/es unknown
- 2022-07-08 IL IL309937A patent/IL309937A/en unknown
- 2022-07-08 CN CN202280059693.4A patent/CN118355035A/zh active Pending
- 2022-07-08 US US18/577,374 patent/US20240318176A1/en active Pending
- 2022-07-08 CA CA3226365A patent/CA3226365A1/en active Pending
- 2022-07-08 WO PCT/US2022/073527 patent/WO2023283613A1/en not_active Ceased
- 2022-07-08 AU AU2022307086A patent/AU2022307086A1/en active Pending
- 2022-07-08 EP EP22838585.2A patent/EP4367147A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024525611A5 (https=) | ||
| JP2024525613A5 (https=) | ||
| JP2024525612A5 (https=) | ||
| JP2024527362A5 (https=) | ||
| JP2024525610A5 (https=) | ||
| IL309937A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309935A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309912A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309911A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309909A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| JP2023510350A5 (https=) | ||
| JP2023535073A5 (https=) | ||
| US20240325558A1 (en) | Muscle targeting complexes and uses thereof for treating myotonic dystrophy | |
| JP7803926B2 (ja) | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 | |
| US11771776B2 (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309936A (en) | Muscle targeting complexes and formulations for the treatment of dystrophinopathy | |
| US20230088865A1 (en) | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy | |
| US20240117356A1 (en) | Muscle targeting complexes and uses thereof for treating myotonic dystrophy | |
| US20250099603A9 (en) | Muscle targeting complexes and uses thereof for treating friedreich's ataxia | |
| JP2024540199A5 (https=) | ||
| JP2024524222A5 (https=) | ||
| JP2023509793A5 (https=) | ||
| JP2024540199A (ja) | ジストロフィノパチーを処置するための筋標的化複合体 | |
| IL316206A (en) | Dosage of muscle targeting complexes for the treatment of myotonic dystrophy | |
| JP2025512468A5 (https=) |